These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 25854266)

  • 1. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
    Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
    Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients.
    Morena M; Dupuy AM; Jaussent I; Vernhet H; Gahide G; Klouche K; Bargnoux AS; Delcourt C; Canaud B; Cristol JP
    Nephrol Dial Transplant; 2009 Nov; 24(11):3389-97. PubMed ID: 19574342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients.
    Morena M; Jaussent I; Halkovich A; Dupuy AM; Bargnoux AS; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
    PLoS One; 2012; 7(5):e36175. PubMed ID: 22567137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin: Another vascular calcification inhibitor?
    Claes KJ; Viaene L; Heye S; Meijers B; d'Haese P; Evenepoel P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3221-8. PubMed ID: 23788689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.
    Guven S; Gokce I; Cicek N; Yaman A; Vatansever P; Alpay H
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1383-1390. PubMed ID: 33068383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
    Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
    Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
    Pelletier S; Confavreux CB; Haesebaert J; Guebre-Egziabher F; Bacchetta J; Carlier MC; Chardon L; Laville M; Chapurlat R; London GM; Lafage-Proust MH; Fouque D
    Osteoporos Int; 2015 Aug; 26(8):2165-74. PubMed ID: 25910747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects.
    Stępień E; Fedak D; Klimeczek P; Wilkosz T; Banyś RP; Starzyk K; Bazanek M; Pasowicz M
    Hypertens Res; 2012 May; 35(5):531-8. PubMed ID: 22278625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
    Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
    Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study.
    Hsu BG; Liou HH; Lee CJ; Chen YC; Ho GJ; Lee MC
    Medicine (Baltimore); 2016 Apr; 95(15):e3300. PubMed ID: 27082570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.
    Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y
    Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
    Viaene L; Behets GJ; Claes K; Meijers B; Blocki F; Brandenburg V; Evenepoel P; D'Haese PC
    Nephrol Dial Transplant; 2013 Dec; 28(12):3024-30. PubMed ID: 23605174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients.
    Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E
    Nephron; 2016; 132(3):181-90. PubMed ID: 26890570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes.
    Maser RE; Lenhard MJ; Sneider MB; Pohlig RT
    Endocr Pract; 2015 Jan; 21(1):14-22. PubMed ID: 25100392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease.
    Mesquita M; Demulder A; Damry N; Mélot C; Wittersheim E; Willems D; Dratwa M; Bergmann P
    Clin Chem Lab Med; 2009; 47(3):339-46. PubMed ID: 19676147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study.
    Brandenburg VM; Kramann R; Koos R; Krüger T; Schurgers L; Mühlenbruch G; Hübner S; Gladziwa U; Drechsler C; Ketteler M
    BMC Nephrol; 2013 Oct; 14():219. PubMed ID: 24112318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
    Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM;
    Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.
    Gršković A; Ćelić T; Španjol J; Markić D; Devčić B; Bobinac D; Rački S
    Acta Clin Croat; 2023 Jul; 62(Suppl2):46-52. PubMed ID: 38966016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.